DERM JOURNEY MEDICAL CORP

Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022

Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022

Company to host conference call to discuss financial results and provide a corporate update on November 10, 2022 at 4:30 p.m. ET

SCOTTSDALE, Ariz., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its third quarter 2022 financial results after the U.S. financial markets close on Thursday, November 10, 2022. Journey Medical management will conduct a conference call and audio webcast on November 10, 2022 at 4:30 p.m. ET.

To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to . Please note that registered participants will receive their dial-in number upon registration.

A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, , and will remain available for replay for approximately 30 days after the conference call.

About Journey Medical Corporation

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is focused on identifying, acquiring, developing and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model. The company currently markets eight products that help treat and heal common skin conditions. The Journey Medical team is comprised of industry experts with extensive experience commercializing some of the most successful prescription dermatology brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit

Company Contact:

Jaclyn Jaffe

Journey Medical Corporation

(781) 652-4500

Media Relations Contact:

Tony Plohoros

6 Degrees

(908) 591-2839



EN
03/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on JOURNEY MEDICAL CORP

 PRESS RELEASE

Journey Medical Corporation to Present at the Emerging Growth Conferen...

Journey Medical Corporation to Present at the Emerging Growth Conference SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Emerging Growth Conference on Wednesday, August 20, 2025 at 12:...

 PRESS RELEASE

Journey Medical Corporation Reports Second Quarter 2025 Financial Resu...

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Second quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commerc...

 PRESS RELEASE

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell o...

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the management team of Journey Medical will ring the closing bell at the Nasdaq MarketSite in Times Square on Monda...

 PRESS RELEASE

Journey Medical Corporation to Announce Second Quarter 2025 Financial ...

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025 Company to host conference call to discuss financial results and provide a corporate update on August 12, 2025 at 4:30 p.m. ET SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today ann...

 PRESS RELEASE

Journey Medical Corporation Announces Expanded Payer Coverage for Emro...

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™ Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOTTSDALE, Ariz., July 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological co...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch